Multiple Sclerosis Treatment With Autologous Hematopoietic Stem Cell Transplantation in the Netherlands

This study is following patients with relapsing-remitting multiple sclerosis (RRMS) — a form of MS characterized by episodes of worsening followed by partial recovery — who have been approved and are receiving autologous hematopoietic stem cell transplantation (aHSCT) in the Netherlands. This procedure uses the patient's own immune cells to reset the immune system. The study compares these patients' outcomes to those receiving standard MS medications. **You may be eligible if...** - You have relapsing-remitting multiple sclerosis - You have been approved to receive autologous stem cell transplantation (aHSCT) according to Dutch national criteria **You may NOT be eligible if...** - You have contraindications to the medications used in aHSCT - You have serious comorbid conditions that make the transplant unsafe - You have severe clinical depression - You have active addiction to drugs or alcohol - You have active infections including tuberculosis, hepatitis, HIV, cytomegalovirus, herpes, or others - You have an active or prior malignancy (other than local basal cell skin cancer or cervical carcinoma in situ) Talk to your doctor to see if this trial is right for you.